Fundraising Fox
Araceli Biosciences
Tigard, US · Founded 2022 · Oregon corporation
Find your way into Araceli Biosciences
164 people in our graph share verified history with the Araceli Biosciences team — schools, employers, funds. One of them is your warm intro.
Sarah Alfaddaunlockedknows Matt Beaudet · together at Life Technologies (overlapped)
×11knows the team · via Life Technologies
Araceli Biosciences builds High Content Imaging platforms and software that provide real-time image analysis and analysis-ready data for therapeutic and drug discovery research. Its tools serve researchers screening compounds, pairing imaging hardware with AI-driven analysis to speed candidate selection in the drug discovery pipeline.
Founders & leadership
MB
Matt BeaudetPresident & CEOMatt Beaudet spent 15 years in scientific and product leadership roles at Molecular Probes, Invitrogen, and Life Technologies, contributing to launches of Qubit, Countess, and other life science instruments; he later co-founded and led InVivo Biosystems for over a decade before becoming President and CEO of Araceli Biosciences, which develops high-throughput cellular imaging and AI-driven analysis platforms for drug discovery.
JH
Jeff HarrisNamed on SEC filing
Board
Reported raises · per SEC filings
Form D private placements$14.5M disclosed across 2 rounds · 2023–2024
▶$12.2MraisedDec 2025 · 28 investors · Other TechnologyRule 506(b)
▶$12.2MraisedDec 2025 · 28 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Matt BeaudetExecutive Officer, Director
- Kirk MalloyDirector
- Sean O'NeillDirector
- Shawn MacDonaldExecutive Officer
- Samraat RahaDirector
- Kevin GabeleinDirector
- J. William FreytagDirector
- William CortelyouDirector
- Bruce RhineDirector
- Offering amount
- $14.1M
- Amount sold
- $12.2M
- First sale
- Dec 2024
- Incorporated
- Corporation, Oregon, 2022
- Federal exemptions
- 06b
▶$2.2MraisedApr 2023 · 3 investors · Other Health CareRule 506(b)
▶$2.2MraisedApr 2023 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kirk MalloyDirector
- J. William FreytagDirector
- Shawn MacDonaldExecutive Officer
- Sean O'NeillDirector
- Kevin GabeleinDirector
- Jeff HarrisExecutive Officer
- William B CortelyouDirector
- Bruce RhineDirector
- Scott IglExecutive Officer
- Samraat RahaDirector
- Offering amount
- $4M
- Amount sold
- $2.2M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapOsmosis49 shared keywordsOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.
Abcam46 shared keywordsSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.
Oup38 shared keywordsOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
Companies competing with Araceli Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Araceli Biosciences do?
- Araceli Biosciences builds High Content Imaging platforms and software that provide real-time image analysis and analysis-ready data for therapeutic and drug discovery research. Its tools serve researchers screening compounds, pairing imaging hardware with AI-driven analysis to speed candidate selection in the drug discovery pipeline.
- How much funding has Araceli Biosciences raised?
- Araceli Biosciences has disclosed $14.5M raised across 2 rounds.
- Where is Araceli Biosciences headquartered?
- Araceli Biosciences is headquartered in Tigard, US.